Tubulis today presented comprehensive preclinical data on its two lead antibody-drug conjugate (ADC) candidates TUB-030 and TUB-040 at this year's Annual Meeting of the American Association for Cancer Research (AACR) in San Diego. The poster.
/PRNewswire/ Kernal Biologics, Inc. (Kernal Bio) a development-stage mRNA-technology company developing cancer therapeutics designed to improve patients .